Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 5/20 | 0.51 |
| ▸ | RAD52 | P43351 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | TTR | P02766 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GSR | P00390 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27534825 | 0.93 | TOP2A (0.58) | TOP2APOLBRAD52KDM4EALDH1A1 | |
| SCHEMBL27513252 | 0.92 | TOP2A (0.54) | TOP2APOLBRAD52KDM4EALDH1A1 | |
| SCHEMBL3360006 | 0.83 | POLB (0.67) | TOP2APOLBRAD52KDM4EALDH1A1 | |
| SCHEMBL28021793 | 0.78 | TOP2A (0.77) | TOP2APOLBRAD52KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL27538864 | 0.77 | TOP2A (0.75) | TOP2APOLBRAD52KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL27513613 | 0.77 | TOP2A (0.75) | TOP2APOLBRAD52KDM4EALDH1A1 | |
| SCHEMBL15298610 | 0.76 | TOP2A (0.58) | TOP2APOLBRAD52KDM4EALDH1A1 | |
| SCHEMBL6782090 | 0.76 | POLB (0.60) | POLBKDM4EALDH1A1GAARAB9A | |
| SCHEMBL11060672 | 0.76 | KDM4E (0.51) | POLBRAD52KDM4EALDH1A1GAA | |
| SCHEMBL15867898 | 0.75 | POLB (0.59) | TOP2APOLBRAD52KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101676268-B | Frangible compounds for pathogen inactivation | CERUS CORP | 2013-09-25 | — | — | CN | disclosed |
| CN-1248245-B | Friable compounds for pathogen inactivation | CERUS CORP | 2012-07-04 | — | — | CN | disclosed |
| CN-101676268-A | frangible compounds for pathogen inactivation | CERUS CORP | 2010-03-24 | — | — | CN | disclosed |
| US-20040029897-A1 | Frangible compounds for pathogen inactivation | CERUS CORPORATION (US) | 2004-02-12 | — | — | US | disclosed |
| EP-1364944-A1 | Frangible Compounds for Pathogen Inactivation | Cerus Corporation (US) | 2003-11-26 | — | — | EP | disclosed |
| EP-1021414-B1 | FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION | CERUS CORP (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6514987-B1 | Useful for inactivating pathogens in a material, such as a blood product, and then degrades to breakdown products | CERUS CORPORATION | 2003-02-04 | — | — | US | disclosed |
| CN-1270630-A | Method of treating leukocytes, leukocyte compositions and methods of use thereof | CERUS CORP (US) | 2000-10-18 | — | — | CN | disclosed |
| EP-1021414-A1 | FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION | Cerus Corporation (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6093725-A | A BINDER FOR DEACTIVATING PATHOGENS IN A BLOOD SAMPLE TO BIND NUCLEIC ACID BY COVALENT LINKAGE | CERUS CORPORATION (US) | 2000-07-25 | — | — | US | disclosed |
| WO-1998030545-A9 | FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION | — | 1998-12-30 | — | — | WO | disclosed |
| WO-1998030545-A1 | FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION | CERUS CORPORATION (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029897-A1 | Frangible compounds for pathogen inactivation | TIAL1, PRF1, DNASE1 | TOP2A 1045/4885POLB 70/4885RAD52 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.